SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-023625
Filing Date
2021-05-05
Accepted
2021-05-05 07:05:28
Documents
14
Period of Report
2021-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eypt-8k_20210505.htm   iXBRL 8-K 36560
2 EX-99.1 eypt-ex991_6.htm EX-99.1 216440
3 GRAPHIC g2wylfc1qsf5000001.jpg GRAPHIC 5168
  Complete submission text file 0001564590-21-023625.txt   400439

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eypt-20210505.xsd EX-101.SCH 5784
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE eypt-20210505_lab.xml EX-101.LAB 18714
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eypt-20210505_pre.xml EX-101.PRE 11181
7 EXTRACTED XBRL INSTANCE DOCUMENT eypt-8k_20210505_htm.xml XML 3421
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 21891126
SIC: 3826 Laboratory Analytical Instruments
Office of Life Sciences